CD137 as an Adjuvant for Adoptive T Cell Therapy and Bone Marrow Transplantation

Adoptive transfer of antigen specific T lymphocytes is certainly a promising strategy for cancer treatment (Dudley and Rosenberg, 2003), as well as for chronic or latent viral infections (Moss and Rickinson, 2005). Several approaches are possible which share in common the obtainment of autologous lymphocytes that are stimulated with antigen in vitro and then artificially expanded for infusion. In these treatments interleukin-2 is commonly coadministered to keep injected lymphocytes alive and...

Effects of CD137 Engagement on CD8 T Cells in vivo

Ligation of CD137 on naive T cells by CD137L or CD137 antibody in the absence of TCR signal does not induce detectable responses DeBenedette et al., 1997 Pollok et al., 1993 . Because naive T cells do not express detectable CD137 Cannons etal., 2001 Pollok et al., 1995 , it is thus possible that TCR is required for upregulation of CD137 on T cell surface. Studies of CD137 expression in vitro indicate that CD137 is expressed 24 h after activation with peak expression at 48-72 h Cannons etal.,...

CD137L Structure and Expression

CD137L is a 34 kD type II membrane glycoprotein with a carboxy-terminal extracellular domain and its gene is on chromosome 17 in the mouse Goodwin et al., 1993 . Although human CD137 ligand huCD137L is present in both T and B cells of the peripheral blood, the ligand is preferentially expressed in primary B cells and B cell lines. Daudi, a B cell lymphoma, is one of the B cell lines with the highest number of ligand molecules Zhou et al., 1995 . Scatchard analysis gave a kd of 1.4 x 10-9 M and...